Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S. - Sarepta Therapeutics
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 21, 2025-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Today, Sarepta Therapeutics notified the U.S. Food and Drug Adminis…